News Related to Imjudo

Related coverage linked through entity extraction aliases.

RAMPART Trial: Durvalumab Monotherapy Lacks DFS Benefit in Resected RCC; Combination Shows Benefit in High-Risk Patients

Jun 04, 2026

The phase 3 RAMPART trial updated results show adjuvant durvalumab monotherapy did not significantly improve disease-free survival in resected renal cell carcinoma, while the durvalumab plus tremelimumab combination showed benefit in high-risk patients. Real-world treatment decisions are also shaped by patient-specific factors.

AstraZeneca Invests $15B in China as Former Executive Faces Charges

Mar 04, 2026

AstraZeneca announced a $15 billion investment in Chinese R&D facilities through 2030, elevating China to a global innovation hub, while former China chief Leon Wang faces charges for unlawful data collection, illegal trade, and medical insurance fraud.